Results 41 to 50 of about 5,282,959 (357)

Global burden of oesophageal and gastric cancer by histology and subsite in 2018

Gut, 2020
Objectives To provide updated estimates of the global burden of oesophageal and gastric cancer by subsite and type. Methods Using data from population-based cancer registries, proportions of oesophageal adenocarcinoma (OAC) and squamous cell carcinoma ...
M. Arnold, J. Ferlay, M. I. van Berge Henegouwen, I. Soerjomataram   +3 more
semanticscholar   +1 more source

Korean Gastric Cancer Association-Led Nationwide Survey on Surgically Treated Gastric Cancers in 2019

Journal of Gastric Cancer, 2021
Purpose The Korean Gastric Cancer Association (KGCA) has been conducting nationwide surveys on patients with surgically treated gastric cancer, every 5 years, since 1995. This study details the results of the survey conducted in 2019.

semanticscholar   +1 more source

Gastric Cancer and Gastric Microbiome

The Korean Journal of Gastroenterology, 2023
Gastric cancer remains a significant disease burden in Korea, with Helicobacter pylori infections being the most crucial risk factor. With the advent of next-generation sequencing, the role of gastric microbiota in gastric cancer has attracted increasing attention.
openaire   +3 more sources

Is the Reinitiation of Antiplatelet Agents Safe at 1 Week after Gastric Endoscopic Submucosal Dissection? Assessment of Bleeding Risk Using the Forrest Classification

Gut and Liver, 2017
Background/AimsDelayed bleeding after gastric endoscopic submucosal dissection (ESD) commonly occurs within 3 days, but it may also occur after 1 week following ESD, especially in antiplatelet agent users.
Jong Yeul Lee, Chan Gyoo Kim, Soo-Jeong Cho, Young-Il Kim, Il Ju Choi   +4 more
doaj   +1 more source

Recurrence after ESD curative resection for early gastric cancer

Surgical Case Reports, 2021
Background Endoscopic submucosal dissection (ESD) is gaining ground as a minimally invasive treatment for early gastric cancer (EGC) that has a negligible risk of lymph node metastasis.
Ayako Kamiya, Hitoshi Katai, Kenichi Ishizu, Takeyuki Wada, Tsutomu Hayashi, Sho Otsuki, Yukinori Yamagata, Takaki Yoshikawa, Shigeki Sekine, Tomohiko Nishi, Yuka Kawasaki, Takafumi Ito, Hideharu Domoto   +12 more
doaj   +1 more source

Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035

Gut, 2020
Objectives The incidence of gastric cancer continues to decrease globally, approaching levels that in some populations could define it as a rare disease.
M. Arnold, Jin Young Park, M. C. Camargo, N. Lunet, D. Forman, I. Soerjomataram   +5 more
semanticscholar   +1 more source

A novel protein encoded by circMAPK1 inhibits progression of gastric cancer by suppressing activation of MAPK signaling

Molecular Cancer, 2021
Background A novel type of noncoding RNA, circRNA has been reported to participate in the occurrence and development of diseases through many mechanisms.
T. Jiang, Yiwen Xia, Jialun Lv, Bowen Li, Ying Li, Sen Wang, Z. Xuan, Li Xie, Shengkui Qiu, Zhongyuan He, Linjun Wang, Zekuan Xu   +11 more
semanticscholar   +1 more source

Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial

BMC Gastroenterology, 2021
Background This randomized, open-label trial aimed to compare the efficacy of 10-day bismuth-containing quadruple therapy (BQT) with 7-day proton-pump inhibitor-clarithromycin containing standard triple therapy (STT) as an empirical first-line ...
Young-Il Kim, Jong Yeul Lee, Chan Gyoo Kim, Boram Park, Jin Young Park, Il Ju Choi   +5 more
doaj   +1 more source

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer

Journal for ImmunoTherapy of Cancer, 2021
Background Durable efficacy of immune checkpoint blockade (ICB) occurred in a small number of patients with metastatic gastric cancer (mGC) and the determinant biomarker of response to ICB remains unclear.
D. Zeng, Jiani Wu, Hui‐yan Luo, Yong Li, Jian‐jun Xiao, Jian-jun Peng, Zilan Ye, R. Zhou, Yunfang Yu, Gaofeng Wang, N. Huang, Jianhua Wu, Xiaoxiang Rong, Li Sun, Huiying Sun, Wenjun Qiu, Yichen Xue, J. Bin, Y. Liao, Nailin Li, Min Shi, Kyoung-Mee Kim, W. Liao   +22 more
semanticscholar   +1 more source

Construction of ovarian metastasis‐related immune signature predicting prognosis of gastric cancer patients

Cancer Medicine, 2023
Background Ovarian metastasis (OM) results in poor survival of gastric cancer (GC) patients. While immunotherapy has emerged as a promising approach for late‐stage GC, validated immune‐related prognostic signatures still remain in need. In this study, we
Jianpeng Gao, Shiying Huo, Yu Zhang, Zhenxiong Zhao, Hongda Pan, Xiaowen Liu   +5 more
doaj   +1 more source